财经首页 | 新浪首页 | 新浪导航
查看完整行情页>>

|

货币单位:美元(USD)

亚力兄制药

Alexion Pharmaceuticals, Inc. (alxn)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
提示:交易结束
Christophe Hotermans Christophe Hotermans currently works at Alexion Pharmaceuticals, Inc., as Senior Vice President & Head-Medical Affairs from 2021.
Patryk Mikucki Patryk Mikucki is currently working as the Vice President of Clinical Research at Alexion Pharmaceuticals, Inc. and as the Vice President at Astrazeneca Pharma Poland SP zoo. He is also a Member of the Supervisory Board at Scope Fluidics SA. Dr. Mikucki has an MBA from the University of Illinois and a doctorate from the University of Life Sciences in Lublin.
Morgan Sanford Morgan Sanford is currently working as the Chief of Staff at Alexion Pharmaceuticals, Inc. Prior to this, they completed an undergraduate degree at Hamilton College (New York) and an MBA at The Leonard N Stern School of Business.
Sean Christie Sean Christie currently works at Alexion Pharmaceuticals, Inc., as Chief Financial & Administration Officer from 2021.
Seng H. Cheng Seng H. Cheng currently works at Alexion Pharmaceuticals, Inc., as Senior VP, Head-Research & Product Development from 2023.
Ruth Diazaraque Ruth Diazaraque currently works at Alexion Pharmaceuticals, Inc., as Vice President-Research & Development from 2023.
Marc Pierre Jean Dunoyer Marc Pierre Jean Dunoyer is currently the Chief Executive Officer at Alexion Pharmaceuticals, Inc. He is also the Chairman at AstraZeneca KK. In addition, he holds positions as a Director at AstraZeneca UK Ltd., AstraZeneca Intermediate Holdings Ltd., and Acerta Pharma BV. He is an Independent Director at Orchard Therapeutics (Europe) Ltd. and serves as the Chief Strategy Officer at AstraZeneca PLC. In his former roles, Mr. Dunoyer served as the Chairman at GlaxoSmithKline KK from 2010 to 2013. He was also an Outside Director at JCR Pharmaceuticals Co., Ltd. Additionally, he held the position of Independent Non-Executive Director at Orchard Therapeutics Plc from 2018 to 2024. He served as the President-Asia Pacific at Hoechst Marion Roussel SA. Furthermore, he was the Global Head-Rare Diseases Unit at GSK Plc from 2012 to 2013. Mr. Dunoyer obtained an MBA from Hautes Etudes Commerciales and completed his graduate studies at Université de Paris IV Paris-Sorbonne.